LONDON, August 26, 2010 /PRNewswire/ -- 2009 and 2010 have seen some of the biggest mergers, acquisitions and licensing activities the pharmaceutical industry has undergone in a very long time. In light of dwindling pipeline products, impending patent expirations for several blockbuster drugs, tight budgets and cost cuts due to the recession, several major pharmaceutical companies are looking at licensing promising drug compounds from biotech or other pharmaceutical companies to remain competitive in the market.
(Logo: http://photos.prnewswire.com/prnh/20081117/FSLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)
In response to these developments, Frost Sullivan has organised a complimentary web conference, entitled Pharma-Biotech Licensing Deals - Stopgap Option or Way of the Future?, to take place on Thursday, 2nd September 2010, at 2 p.m. BST. Research Analyst, Ms. Swetha Shantikumar, will give an analysis of licensing trends by deal value, geographic region, therapeutic area and stage of drug development.
Option-based deals are a leading choice for the large pharmas to hedge financial risk in tough economic times, while exploiting opportunities to license promising drug candidates in early stages of clinical development, observes Shantikumar. This will typically yield better return-on-investments in a less competitive environment.
This web conference will benefit top management in pharmaceutical and biotechnology companies, venture capital and private equity firms as wells as angel investors by providing an analysis of emerging trends and future forecasts in the pharma-biotech licensing world.
To participate in this complimentary briefing, please email Katja Feick at katja.feick@frost.com with your full contact details. Upon receipt of the above information, a registration link will be e-mailed to you. You may also register to receive a recorded version of the briefing at anytime by submitting the aforementioned contact details.
About Frost Sullivan
Frost Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
Contact: Katja Feick Corporate Communications - Europe P: +49-(0)-69-7703343 E: katja.feick@frost.com http://www.frost.com Twitter: twitter.com/frost_sullivan
SOURCE: Frost SOURCE: Sullivan
CONTACT: Katja Feick, Corporate Communications - Europe, Frost Sullivan,+49-(0)-69-7703343, katja.feick@frost.com
Comments